活动性中轴型脊柱关节炎患者接受培塞利珠单抗治疗后客观炎症反应与临床反应之间潜在脱节的探索性分析
该事后分析纳入136例活动性中轴型脊柱关节炎(axSpA)患者,评估培塞利珠单抗(CZP)治疗12周后客观炎症指标与临床复合结局改善之间的关系。结果显示多数患者客观炎症指标(CRP、MRI评分)改善≥50%,但不足半数患者达到临床复合结局(BASDAI、ASDAS)改善≥50%,提示客观炎症反应与临床反应之间存在潜在脱节。
要点
- CZP治疗12周后,CRP改善≥50%者为136/136(100.0%),Berlin评分改善≥50%者为73/136(53.7%),SPARCC骶髂关节评分改善≥50%者为71/136(52.2%)。
- 临床复合结局改善≥50%者不足半数:BASDAI为64/136(47.1%),ASDAS为66/136(48.5%)。
- 在个体患者层面,多数患者MRI/CRP炎症指标改善≥50%并未转化为临床反应的相似改善。
核心结论
- 活动性axSpA患者中客观炎症指标与临床结局反应之间存在潜在脱节。
- 仅以临床反应指标作为试验终点可能低估抗炎治疗效应。
研究设计与样本
- 事后分析,评估活动性axSpA患者接受12周CZP治疗后客观炎症指标与临床结局的关系。
- 纳入136例患者(放射学axSpA 76例,非放射学axSpA 60例)。
- 数据来自两名独立阅片者在四轮MRI阅片活动中的结果,各变量采用重复测量混合模型合并。
主要发现
- CZP治疗后,多数患者CRP、ASspiMRI-a Berlin评分和SPARCC骶髂关节评分降低≥50%(CRP:136/136[100.0%];Berlin:73/136[53.7%];SPARCC骶髂关节:71/136[52.2%]),且常降低≥75%。
- 放射学axSpA和非放射学axSpA患者中,临床反应改善≥50%者不足半数(BASDAI:64/136[47.1%];ASDAS:66/136[48.5%])。
- 在个体患者层面,多数患者MRI/CRP炎症指标改善≥50%未转化为临床反应的相似改善。
关键数值与推荐
- 临床复合结局改善≥50%:BASDAI为64/136(47.1%),ASDAS为66/136(48.5%)。
- 客观炎症指标改善≥50%:CRP为136/136(100.0%),ASspiMRI-a Berlin评分为73/136(53.7%),SPARCC骶髂关节评分为71/136(52.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This post hoc analysis evaluated the relationship between objective measures of inflammation and clinical outcomes following 12 weeks of certolizumab pegol (CZP) treatment in patients with active axial spondyloarthritis (axSpA). METHODS: We report the proportion of patients achieving ≥50% and ≥75% improvements in clinical composite outcome measures of disease activity (Axial Spondyloarthritis Disease Activity Score [ASDAS], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]) and objective measures of inflammation (C reactive protein [CRP], Ankylosing Spondylitis spine MRI score [ASspiMRI-a] Berlin score and Spondyloarthritis Research Consortium of Canada [SPARCC] MRI Sacroiliac Joints [SIJ] score) following 12 weeks of CZP treatment. Data from two independent readers over four MRI reading campaigns were pooled using a mixed model with repeated measures for each variable. RESULTS: 136 patients (radiographic axSpA [r-axSpA]: 76; non-radiographic axSpA [nr-axSpA]: 60) were included. Following CZP treatment, CRP, ASspiMRI-a Berlin score and SPARCC SIJ score were reduced by ≥50% in most patients (CRP: 136/136 [100.0%]; Berlin: 73/136 [53.7%]; SPARCC SIJ: 71/136 [52.2%]), and often by ≥75%. Less than half of patients with r-axSpA and nr-axSpA showed ≥50% reduction in clinical responses (BASDAI: 64/136 [47.1%]; ASDAS: 66/136 [48.5%]). These results were also observed at the individual patient level; ≥50% improvements in MRI/CRP inflammatory measures did not translate into similar improvements in clinical responses for most patients. CONCLUSION: There is a potential disconnect between objective measures of inflammation and clinical outcome responses in patients with axSpA. The use of only clinical response measures as trial endpoints may underestimate anti-inflammatory treatment effects. TRIAL REGISTRATION NUMBER: NCT01087762.
引用
- Rudwaleit M, Marzo-Ortega H, Navarro-Compán V, et al. Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis. RMD Open. 2024. PMID: 39209369. doi:10.1136/rmdopen-2024-004369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。